Effect of renal function on pemetrexed-induced haematotoxicity - Wikidata - wikimedia - TriplyDB

Effect of renal function on pemetrexed-induced haematotoxicity

Effect of renal function on pemetrexed-induced haematotoxicity

http://www.wikidata.org/entity/Q33432955

about

Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer.

P2860

Q47715888-3F281B0F-8550-4E59-93CA-A32B2BD8457A

P2860

Effect of renal function on pemetrexed-induced haematotoxicity

http://www.wikidata.org/entity/Q33432955

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Effect of renal function on pemetrexed-induced haematotoxicity

@ast

Effect of renal function on pemetrexed-induced haematotoxicity

@en

type

label

Effect of renal function on pemetrexed-induced haematotoxicity

@ast

Effect of renal function on pemetrexed-induced haematotoxicity

@en

prefLabel

Effect of renal function on pemetrexed-induced haematotoxicity

@ast

Effect of renal function on pemetrexed-induced haematotoxicity

@en

P1433

Q33432955-19234E61-C84A-4597-93D4-3DD30A889978

P1476

Q33432955-CA80900F-ACE8-4954-AD76-F46F77566833

P2093

Q33432955-239BA0DB-4BA9-49F2-958C-0E4BB5C918B1

Q33432955-3BAA664F-A245-4434-8818-EC96A8795C95

Q33432955-3BFD00E4-8ACC-41F1-B940-C72E5F0A2316

Q33432955-3D3B3069-3EEE-4FD4-A9CB-EE3769862433

Q33432955-69982EA0-579B-45BE-ADA1-8A5920A661F3

Q33432955-76C54A2A-3BD2-440B-9B55-02D2BEB233B3

Q33432955-77ED3436-EC25-4BDF-8EC4-081C4DF4A851

Q33432955-7D5D630F-B331-486A-8B28-160DED1A0112

Q33432955-7DFE5D46-05B2-4B36-A3EB-560E64E175FC

Q33432955-7F66D36E-13E3-4D42-A1B0-A8FAA388AA82

P2860

Q33432955-0F14E62E-BC03-466F-AEE1-F6CC816BBF5C

Q33432955-1F359A48-24A0-4361-98EE-752DB5D8C342

Q33432955-1F44A0E1-7FEA-4096-8EE8-2C2BDDF7270E

Q33432955-211D030E-03BD-43D6-A0DA-839E0B3D558A

Q33432955-216816A3-2380-4E3C-9DE9-B3F8C78AEEF3

Q33432955-2906DEA9-4D6D-4553-98AC-79A92CF6C45D

Q33432955-3435AB81-3A96-49A1-A0D2-172A227D0A03

Q33432955-3670EA0F-BB9B-4AFD-85D3-066273C315C2

Q33432955-3F6F30CD-9DB9-499C-9FBC-9F0E9C6053ED

Q33432955-45EA47E9-F832-45C0-8EDF-7233D45C7602

P2888

Q33432955-3A6CC6FB-8060-4FA6-A68D-3E29FF8944D1

P304

Q33432955-0CA934D0-5CAA-4F79-AE7E-97A413756097

P31

Q33432955-5B5565BE-2163-4D2C-BEFA-19F4474F0230

P356

Q33432955-BC10DF38-0C7E-4E5A-AC55-A44FEB88C738

P433

Q33432955-52F6CA20-48B1-4EF6-A4B5-00FCF0BA102B

P478

Q33432955-D753CBBA-8DFB-440E-82EE-0D093392C959

P577

Q33432955-3FE06383-165D-4BFA-A13F-6D859EAA12E9

P6179

Q33432955-259118C0-F898-40AC-A365-734A61D9FDD9

P698

Q33432955-26721343-6413-4A58-B48E-A3DA905953EA

P932

Q33432955-E24416E8-D0D4-4DD9-BF90-B05D35D52771

P356

S00280-016-3078-7

P1433

Cancer Chemotherapy and Pharmacology

P1476

Effect of renal function on pemetrexed-induced haematotoxicity

@en

P2093

Hideki Ohta

http://www.w3.org/2001/XMLSchema#string

Kaori Ito

http://www.w3.org/2001/XMLSchema#string

Kazuyoshi Imaizumi

http://www.w3.org/2001/XMLSchema#string

Kenji Kawada

http://www.w3.org/2001/XMLSchema#string

Kimio Yasuda

http://www.w3.org/2001/XMLSchema#string

Minori Funatsu

http://www.w3.org/2001/XMLSchema#string

Moeko Ujita

http://www.w3.org/2001/XMLSchema#string

Shigeki Yamada

http://www.w3.org/2001/XMLSchema#string

Sumie Murai

http://www.w3.org/2001/XMLSchema#string

Takahiro Hayashi

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

P2888

s00280-016-3078-7

P304

183-189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-016-3078-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1017315212

http://www.w3.org/2001/XMLSchema#string

P698

27286996

http://www.w3.org/2001/XMLSchema#string

P932

4921104

http://www.w3.org/2001/XMLSchema#string